2. Search Result
Search Result
Results for "

LEC

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

2

Peptides

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103039
    TLR7 agonist 2
    1 Publications Verification

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7 agonist 2 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a LEC of 0.4 μM.
    TLR7 agonist 2
  • HY-111358
    TLR7 agonist 1

    		Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7 agonist 1 is a selective TLR7 agonist with an LEC value of 90 nM. TLR7 agonist 1 activates downstream immune regulation and shows no activity against TLR8. TLR7 agonist 1 induces endogenous IFN-α production in mice .
    TLR7 agonist 1
  • HY-B0881
    Acetohexamide
    2 Publications Verification

    		 Potassium Channel Metabolic Disease Cancer
    Acetohexamide is an orally active first-generation sulfonylurea agent used in research related to type 2 diabetes and cancer. Acetohexamide exerts reductase activity in human erythrocytes. Acetohexamide stimulates the pancreas to secrete insulin. Acetohexamide inhibits ATP-sensitive potassium channels in the β cells of the pancreas. Acetohexamide can inhibit the formation of circular chemorepellent induced defects (CCIDs) in lymphendothelial cell (LEC) monolayers. Acetohexamide inhibits markers of epithelial-to-mesenchymal-transition and migration. Acetohexamide suppresses the synthesis of 12(S)-HETE. Acetohexamide can potentiate hypoglycaemic action .
    Acetohexamide
  • HY-P3695
    VSPPLTLGQLLS

    		FGFR Cancer
    VSPPLTLGQLLS is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation .
    VSPPLTLGQLLS
  • HY-177300
    TLR7/8 agonist 13

    		Toll-like Receptor (TLR) HBV IFNAR Interleukin Related Infection Inflammation/Immunology
    TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and TLR8 (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus .
    TLR7/8 agonist 13
  • HY-RS02085
    CCL16 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CCL16 Human Pre-designed siRNA Set A contains three designed siRNAs for CCL16 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CCL16 Human Pre-designed siRNA Set A
    CCL16 Human Pre-designed siRNA Set A
  • HY-P3695A
    VSPPLTLGQLLS TFA

    		FGFR Cancer
    VSPPLTLGQLLS TFA is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS TFA inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation .
    VSPPLTLGQLLS TFA
  • HY-B0881R
    Acetohexamide (Standard)

    		Reference Standards Potassium Channel Metabolic Disease Cancer
    Acetohexamide (Standard) is the analytical standard of Acetohexamide. This product is intended for research and analytical applications. Acetohexamide is an orally active first-generation sulfonylurea agent used in research related to type 2 diabetes and cancer. Acetohexamide exerts reductase activity in human erythrocytes. Acetohexamide stimulates the pancreas to secrete insulin. Acetohexamide inhibits ATP-sensitive potassium channels in the β cells of the pancreas. Acetohexamide can inhibit the formation of circular chemorepellent induced defects (CCIDs) in lymphendothelial cell (LEC) monolayers. Acetohexamide inhibits markers of epithelial-to-mesenchymal-transition and migration. Acetohexamide suppresses the synthesis of 12(S)-HETE. Acetohexamide can potentiate hypoglycaemic action .
    Acetohexamide (Standard)
  • HY-103039R
    TLR7 agonist 2 (Standard)

    		Reference Standards Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7 agonist 2 (Standard) is the analytical standard of TLR7 agonist 2 (HY-103039). This product is intended for research and analytical applications. TLR7 agonist 2 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a LEC of 0.4 μM.
    TLR7 agonist 2 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: